drugset / Trial / NCT06625242
A Study of Filgotinib in Korean Participants With Rheumatoid Arthritis
NaSingle-groupOpen-labelTreatment
Summary
The primary purpose of this study is to assess the percentage of participants achieving an American College of Rheumatology (ACR) 20 percent (%) Improvement (ACR20) response at Week 12 of the administration of the investigational product.
Timeline
- Start
- 2024-10-22
- Primary completion
- 2026-01-21
- Completion
- 2026-02-25
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Filgotinib | Small molecule | 100 mg | Oral |
| Subject | Filgotinib | Small molecule | 200 mg | Oral |